121,591 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 121,591 shares of the medical device company's stock, valued at approximately $3,716,000. Raymond James Financial Inc. owned 0.25% of AtriCure as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ATRC. Heck Capital Advisors LLC acquired a new position in AtriCure in the fourth quarter worth $60,000. Venturi Wealth Management LLC lifted its stake in AtriCure by 1,337.6% in the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after buying an additional 2,100 shares in the last quarter. KBC Group NV lifted its stake in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after buying an additional 932 shares in the last quarter. R Squared Ltd bought a new position in AtriCure in the fourth quarter valued at approximately $89,000. Finally, AlphaQuest LLC raised its holdings in shares of AtriCure by 855.1% in the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock valued at $155,000 after purchasing an additional 4,532 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.50% of the company's stock.

AtriCure Stock Performance

NASDAQ:ATRC traded up $0.98 during mid-day trading on Tuesday, reaching $34.65. The company's stock had a trading volume of 1,122,803 shares, compared to its average volume of 657,564. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The firm's fifty day moving average price is $34.21 and its two-hundred day moving average price is $34.70. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.71 billion, a P/E ratio of -36.47 and a beta of 1.65.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The business's quarterly revenue was up 13.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.28) EPS. On average, equities analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on ATRC. Stifel Nicolaus upped their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. JMP Securities reissued a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a research note on Monday, February 10th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Needham & Company LLC restated a "buy" rating and issued a $51.00 target price on shares of AtriCure in a report on Thursday, March 27th. Finally, JPMorgan Chase & Co. lowered their target price on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, AtriCure currently has an average rating of "Moderate Buy" and an average price target of $49.44.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.